References

  1. Virani SS, Alonso A, Aparicio HJ, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2021 Heart disease and stroke statistics update fact sheet at-a-glance. https://www.heart.org/-/media/phd-files-2/science-news/2/2021-heart-and-stroke-stat-update/2021_heart_disease_and_stroke_statistics_update_fact_sheet_at_a_glance.pdf. Accessed May 12, 2021.
  2. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018;328:1-8.
  3. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. https://www.heart.org/-/media/files/about-us/policy-research/fact-sheets/ucm_491543.pdf?la=en. Accessed May 10, 2021.
  4. American Heart Association. HDL (good), LDL (bad) cholesterol and triglycerides. https://www.heart.org/en/health-topics/cholesterol/hdl-good-ldl-bad-cholesterol-and-triglycerides. Accessed May 10, 2021.
  5. Centers for Disease Control and Prevention. Women and heart disease. https://www.cdc.gov/heartdisease/women.htm. Accessed May 10, 2021.
  6. Centers for Disease Control and Prevention. Heart disease facts: https://www.cdc.gov/heartdisease/facts.htm. Accessed May 12, 2021.
  7. American Heart Association. Coronary artery disease – coronary heart disease. https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/coronary-artery-disease. Accessed May 12, 2021.
  8. Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2(1):56-65.
  9. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open. 2019;9(4):e023085.
  10. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
  11. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-366.
  12. What you need to know about dietary supplements. US Food and Drug Administration website. https://www.fda.gov/food/dietarysupplements/usingdietarysupplements/ucm109760.htm. Updated November 2017. Accessed May 10, 2021.
  13. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. April 18, 2016;81(74):22612-22613.
  14. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
  15. Kolber MR, Nickonchuk T, Turgeon R. Do PCSK9 inhibitors reduce cardiovascular events? Can Fam Physician. 2018;64(9):669.
  16. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72(3):314-329.
  17. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):CD004816.
  18. Pharmacy Times. FDA approves first PCSK9 inhibitor. https://www.pharmacytimes.com/news/fda-approves-first-pcsk9-inhibitor. Published July 24, 2015. Accessed May 10, 2021.
  19. MedPage Today. Second PCSK9 inhibitor approved for CV prevention. https://www.medpagetoday.com/cardiology/prevention/79498. Accessed May 10, 2021.
  20. McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory from the American Heart Association. Circulation. 2019;139(9):e44-e54.
  21. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261-1271.
  22. Our World in Data. Does the news reflect what we die from? https://ourworldindata.org/does-the-news-reflect-what-we-die-from. Published May 29, 2019. Accessed May 10, 2021.
  23. American Heart Association. Understand your risks to prevent a heart attack. https://www.heart.org/en/health-topics/heart-attack/understand-your-risks-to-prevent-a-heart-attack. Accessed May 10, 2021.
  24. National Institutes of Health. Atherosclerosis. https://www.nhlbi.nih.gov/health-topics/atherosclerosis. Accessed May 10, 2021.
  25. Furie MB, Mitchell RN. Plaque attack: one hundred years of atherosclerosis in The American Journal of Pathology. Am J Pathol. 2012;180(6):2184-2187.
  26. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.
  27. National Institutes of Health. Heart attack. https://www.nhlbi.nih.gov/health-topics/heart-attack. Accessed May 10, 2021.
  28. National Institutes of Health. Stroke. https://www.nhlbi.nih.gov/health-topics/stroke. Accessed May 10, 2021.
  29. National Institutes of Health MedlinePlus. Triglycerides test. https://medlineplus.gov/lab-tests/triglycerides-test/. Accessed May 10, 2021.
  30. American College of Cardiology CardioSmart. Very high triglycerides. https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides. Accessed May 10, 2021.
  31. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, et al. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.
  32. Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203.
  33. National Institutes of Health MedlinePlus. Triglyceride level. https://medlineplus.gov/ency/article/003493.htm. Accessed May 10, 2021.
  34. American Heart Association. Proactive steps can reduce chances of a second heart attack. https://www.heart.org/en/news/2019/04/04/proactive-steps-can-reduce-chances-of-second-heart-attack. Accessed November 17, 2021.
  35. American Stroke Association. Stroke risk factors not within your control. https://www.stroke.org/en/about-stroke/stroke-risk-factors-not-within-your-control. Accessed November 17, 2021.
  36. National Center for Complementary and Integrative Health. Omega-3 supplements: in depth. https://www.nccih.nih.gov/health/omega3-supplements-in-depth. Updated May 2018. Accessed May 13, 2021.
  37. Goel A, Pothineni NV, Singhal M, Paydak H, Saldeen T, Mehta JL. Fish, Fish Oils and Cardioprotection: Promise or Fish Tale? Int J Mol Sci. 2018;19(12):1-13.
  38. Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018;3(3):225-234.
  39. Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335-338.
  40. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25(1):46-52.
  41. Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467-474.
  42. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5-18.
DOES YOUR HEART NEED MORE?
DISCOVER A PRESCRIPTION TREATMENT OPTION

Click

here
if you are a healthcare professional

Click here to see the commercial.

Full Reference List |Disclaimer | Privacy Policy

The Amarin logo is a registered trademark of the Amarin group of companies. All other trademarks are the property of their respective companies.

© 2021 Amarin Pharma, Inc. Bridgewater, NJ, USA.
All rights reserved.
Contact Us: 1-855-CVTRUTH
The Amarin group of companies is not responsible for material contained on other non-Amarin controlled websites or other social media sites.
AMRN-00373v7   11/21

Amarin